Another key player in China’s biotech ecosystem has landed a pharma deal. On Sunday, Eli Lilly and Insilico Medicine announced a drug discovery collaboration, with

The heart drug that Braveheart Bio licensed from China’s Jiangsu Hengrui Pharmaceuticals has shown promise in a mid-stage trial, according to data released Monday. The

Kailera Therapeutics has filed for an IPO, ​hoping to whet investor appetites with its pipeline of drug candidates for weight loss.

A study has found that undiagnosed heart failure can be detected in people with high-risk diabetes using a simple, GP-led care pathway.

Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.